These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37350280)

  • 1. Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial Fibrillation.
    Kondo T; Jering KS; Jhund PS; Anand IS; Desai AS; Lam CSP; Maggioni AP; Martinez FA; Packer M; Petrie MC; Pfeffer MA; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Solomon SD; McMurray JJV
    Circ Heart Fail; 2023 Jul; 16(7):e010377. PubMed ID: 37350280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation.
    Kondo T; Abdul-Rahim AH; Talebi A; Abraham WT; Desai AS; Dickstein K; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Packer M; Petrie M; Ponikowski P; Rouleau JL; Sabatine MS; Swedberg K; Zile MR; Solomon SD; Jhund PS; McMurray JJV
    Eur Heart J; 2022 Nov; 43(42):4469-4479. PubMed ID: 36017729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.
    Kristensen SL; Mogensen UM; Jhund PS; Rørth R; Anand IS; Carson PE; Desai AS; Pitt B; Pfeffer MA; Solomon SD; Zile MR; Køber L; McMurray JJV
    Circ Heart Fail; 2019 Mar; 12(3):e005766. PubMed ID: 30871349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
    Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
    J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation.
    Kristensen SL; Jhund PS; Mogensen UM; Rørth R; Abraham WT; Desai A; Dickstein K; Rouleau JL; Zile MR; Swedberg K; Packer M; Solomon SD; Køber L; McMurray JJV;
    Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29018174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER.
    Kondo T; Butt JH; Curtain JP; Jhund PS; Docherty KF; Claggett BL; Vaduganathan M; Bachus E; Hernandez AF; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Kosiborod MN; Desai AS; Køber L; Ponikowski P; Sabatine MS; Solomon SD; McMurray JJV
    Circ Heart Fail; 2023 Dec; 16(12):e010898. PubMed ID: 37886880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
    Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stroke and Systemic Embolism and Other Adverse Outcomes of Heart Failure With Preserved and Reduced Ejection Fraction in Patients With Atrial Fibrillation (from the COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation [CODE-AF]).
    Chung S; Kim TH; Uhm JS; Cha MJ; Lee JM; Park J; Park JK; Kang KW; Kim J; Park HW; Choi EK; Kim JB; Kim CS; Lee YS; Shim J; Joung B
    Am J Cardiol; 2020 Jan; 125(1):68-75. PubMed ID: 31699363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction).
    Kristensen SL; Mogensen UM; Jhund PS; Petrie MC; Preiss D; Win S; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Gottdiener JS; Carson PE; McMurray JJ
    Circulation; 2017 Feb; 135(8):724-735. PubMed ID: 28052977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study.
    Zile MR; Jhund PS; Baicu CF; Claggett BL; Pieske B; Voors AA; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD;
    Circ Heart Fail; 2016 Jan; 9(1):. PubMed ID: 26754625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials.
    Abdul-Rahim AH; Perez AC; Fulton RL; Jhund PS; Latini R; Tognoni G; Wikstrand J; Kjekshus J; Lip GY; Maggioni AP; Tavazzi L; Lees KR; McMurray JJ; ;
    Circulation; 2015 Apr; 131(17):1486-94; discussion 1494. PubMed ID: 25810334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
    Cikes M; Planinc I; Claggett B; Cunningham J; Milicic D; Sweitzer N; Senni M; Gori M; Linssen G; Shah SJ; Packer M; Pfeffer M; Zile MR; Anand I; Chiang LM; Lam CSP; Redfield M; Desai AS; McMurray JJV; Solomon SD
    JACC Heart Fail; 2022 May; 10(5):336-346. PubMed ID: 35483796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials.
    Abdul-Rahim AH; Perez AC; MacIsaac RL; Jhund PS; Claggett BL; Carson PE; Komajda M; McKelvie RS; Zile MR; Swedberg K; Yusuf S; Pfeffer MA; Solomon SD; Lip GYH; Lees KR; McMurray JJV;
    Eur Heart J; 2017 Mar; 38(10):742-750. PubMed ID: 28426886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thromboembolisms in atrial fibrillation and heart failure patients with a preserved ejection fraction (HFpEF) compared to those with a reduced ejection fraction (HFrEF).
    Sobue Y; Watanabe E; Lip GYH; Koshikawa M; Ichikawa T; Kawai M; Harada M; Inamasu J; Ozaki Y
    Heart Vessels; 2018 Apr; 33(4):403-412. PubMed ID: 29067492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of physical activity and risk of atrial fibrillation in heart failure with preserved ejection fraction.
    Zhu W; Liang W; Ye Z; Wu Y; He X; Xue R; Wu Z; Zhou Y; Zhao J; Dong Y; Liu C
    Nutr Metab Cardiovasc Dis; 2021 Jan; 31(1):247-253. PubMed ID: 33097408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure.
    Sandhu RK; Hohnloser SH; Pfeffer MA; Yuan F; Hart RG; Yusuf S; Connolly SJ; McAlister FA; Healey JS
    Stroke; 2015 Mar; 46(3):667-72. PubMed ID: 25628308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
    Solomon SD; Rizkala AR; Lefkowitz MP; Shi VC; Gong J; Anavekar N; Anker SD; Arango JL; Arenas JL; Atar D; Ben-Gal T; Boytsov SA; Chen CH; Chopra VK; Cleland J; Comin-Colet J; Duengen HD; Echeverría Correa LE; Filippatos G; Flammer AJ; Galinier M; Godoy A; Goncalvesova E; Janssens S; Katova T; Køber L; Lelonek M; Linssen G; Lund LH; O'Meara E; Merkely B; Milicic D; Oh BH; Perrone SV; Ranjith N; Saito Y; Saraiva JF; Shah S; Seferovic PM; Senni M; Sibulo AS; Sim D; Sweitzer NK; Taurio J; Vinereanu D; Vrtovec B; Widimský J; Yilmaz MB; Zhou J; Zweiker R; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV
    Circ Heart Fail; 2018 Jul; 11(7):e004962. PubMed ID: 29980595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction.
    Shen L; Jhund PS; Anand IS; Carson PE; Desai AS; Granger CB; Køber L; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Swedberg K; Zile MR; McMurray JJV
    Clin Res Cardiol; 2021 Aug; 110(8):1234-1248. PubMed ID: 33301080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial.
    Parkash R; Wells GA; Rouleau J; Talajic M; Essebag V; Skanes A; Wilton SB; Verma A; Healey JS; Sterns L; Bennett M; Roux JF; Rivard L; Leong-Sit P; Jensen-Urstad M; Jolly U; Philippon F; Sapp JL; Tang ASL
    Circulation; 2022 Jun; 145(23):1693-1704. PubMed ID: 35313733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve).
    Böhm M; Perez AC; Jhund PS; Reil JC; Komajda M; Zile MR; McKelvie RS; Anand IS; Massie BM; Carson PE; McMurray JJ;
    Eur J Heart Fail; 2014 Jul; 16(7):778-87. PubMed ID: 24864045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.